The Asia Pacific Mobile ECG Devices Market would witness market growth of 13.2% CAGR during the forecast period (2023-2030). In the year 2021, the Asia Pacific market’s volume surged to 1,761.2 thousand units, showcasing a growth of 18.3% (2019-2022).
Preventive healthcare has gained traction as a healthcare paradigm and mobile ECG devices align seamlessly with this approach. These devices empower individuals to take charge of their health by providing a means to regularly monitor their heart rhythms and detect irregularities. Such proactive monitoring can facilitate early intervention and lifestyle modifications to mitigate the risk of heart disease, underscoring the critical role of mobile ECG technology in preventive care.
Furthermore, the integration of wellness and fitness features into mobile ECG devices has expanded their utility beyond clinical settings. Many of these devices now offer functionalities such as activity tracking, sleep analysis, and stress management, providing users with a holistic view of their overall well-being. The convergence of health and fitness monitoring in a single device resonates with the growing trend of health-conscious individuals seeking all-in-one solutions to monitor and manage their health.
According to the World Health Organization, in the South-east Asia Region, 3.6 million lives are lost every year because of CVDs. Through SEA HEARTS, the "WHO South-East Asia HEARTS initiative," the WHO South-East Asia Region intends to scale up and integrate ongoing initiatives to reduce deaths from CVDs by one-third in this region by 2030. Likewise, the Australian Government states that in 2017–18, 1.2 million adults in Australia, or 6.2% of the population above the age of 18, had one or more conditions related to heart disease, stroke, or vascular disease. 600,000 hospital admissions in 2020–21 had CVD listed as the primary diagnosis. 42,700 deaths, or 25% of all deaths, were attributed to CVD in 2021.
The rising usage of mobile ECG devices in the Asia-Pacific region can be attributed to growing awareness of heart health, lifestyle changes, the aging population, telehealth adoption, wearable integration, preventive healthcare priorities, data privacy, regulatory compliance, cultural factors, and continuous innovation. Mobile ECG devices will become more crucial for managing health and providing cardiac care in the Asia-Pacific region as long as these trends continue.
The China market dominated the Asia Pacific Mobile ECG Devices Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $312.4 Million by 2030. The Japan market is registering a CAGR of 12.4% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 13.9% during (2023 - 2030).
Based on Modality, the market is segmented into Handheld, Band, Pen, and Others. Based on End-use, the market is segmented into Hospitals & Diagnostic Centers, Ambulatory Care, and Homecare. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include New York Plastic Surgical Group, PC (Long Island Plastic Surgical Group), Nihon Kohden Corporation, GE HealthCare Technologies, Inc., Medtronic PLC, iRhythm Technologies, Inc., Koninklijke Philips N.V., OMRON Corporation, Nureca Limited (Dr Trust), EMAY, and AliveCor, Inc.
Scope of the Study
Market Segments covered in the Report:
By Modality (Volume, Thousand Units, USD Billion, 2019-2030)

  • Handheld
  • Band
  • Pen
  • Others


By End-use (Volume, Thousand Units, USD Billion, 2019-2030)

  • Hospitals & Diagnostic Centers
  • Ambulatory Care
  • Homecare


By Country (Volume, Thousand Units, USD Billion, 2019-2030)

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific


Companies Profiled

  • New York Plastic Surgical Group, PC (Long Island Plastic Surgical Group)
  • Nihon Kohden Corporation
  • GE HealthCare Technologies, Inc.
  • Medtronic PLC
  • iRhythm Technologies, Inc.
  • Koninklijke Philips N.V.
  • OMRON Corporation
  • Nureca Limited (Dr Trust)
  • EMAY
  • AliveCor, Inc.


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free